Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct‐Acting Antiviral Treatment Failure in Patients With Hepatitis C?

Direct‐acting antiviral (DAA) therapies have revolutionized the treatment of chronic hepatitis C virus infection, achieving sustained virological response (SVR) rates of >90% even in patients with advanced liver cirrhosis. Having observed an unusual case of repeated DAA therapy failures in a pati...

Full description

Saved in:
Bibliographic Details
Published in:Hepatol Commun
Main Authors: Piecha, Felix, Gänßler, Jan‐Michael, Jordan, Sabine, Ergen, Can, Ittrich, Harald, Kluwe, Johannes, Pischke, Sven, Lohse, Ansgar W., Schulze zur Wiesch, Julian
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Brief Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492468/
https://ncbi.nlm.nih.gov/pubmed/31061950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1337
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items